LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

MRK

111.34

+0.09%↑

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

MRK

111.34

+0.09%↑

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

MRK

111.34

+0.09%↑

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

MRK

111.34

+0.09%↑

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

MRK

111.34

+0.09%↑

Home・Stock List・AbbVie Inc

AbbVie Inc

Closed

SectorHealthcare

202.82 0.84

Buy Sell

Overview

Share price change

24h

Current

Min

201.14

Max

205.19

Key metrics
By Trading Economics
Income	1.6B 1.8B
Sales	-1.6B 15B
P/E Sector Avg	101.049 49.8
EPS	2.65
Dividend yield	3.26
Profit margin	10.928
Employees	57,000
EBITDA	-635M 4.7B

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+25.99% upside

Dividends
By Dow Jones
Dividend yield Sector Avg	3.26% 2.25%
Next Earnings	30 Jul 2026
Next Dividend date	15 May 2026
Next Ex Dividend date	14 Jul 2026

Market Stats
By TradingEconomics
Market Cap	19B 368B
Previous open	201.98
Previous close	202.82

News Sentiment

By Acuity

29%

71%

98 / 346 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

180.37 / 195.54 Support & Resistance

AbbVie Inc Chart

Past performance is not a reliable indicator of future results.

Related News

29 Apr 2026, 12:38 UTC

Earnings

AbbVie Raises Fiscal Year Guidance on Immunology, Neuroscience Growth

4 Feb 2026, 13:20 UTC

Earnings

AbbVie 4Q Revenue Rises on Immunology Growth

29 Apr 2026, 12:41 UTC

Earnings

AbbVie Beats Earnings Estimates, Boosts 2026 Outlook. What It Means for the Stock. -- Barrons.com

29 Apr 2026, 12:23 UTC

Earnings

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

29 Apr 2026, 11:50 UTC

Earnings

AbbVie Raising Adjusted EPS Guidance for FY26 >ABBV

29 Apr 2026, 11:49 UTC

Earnings

AbbVie 1Q Global Humira Rev $688 M >ABBV

29 Apr 2026, 11:48 UTC

Earnings

AbbVie 1Q Global Rinvoq Rev $2.119 B >ABBV

29 Apr 2026, 11:47 UTC

Earnings

AbbVie 1Q Global Net Rev From Oncology Portfolio $1.63B >ABBV

29 Apr 2026, 11:47 UTC

Earnings

AbbVie 1Q Global Skyrizi Rev $4.48B >ABBV

29 Apr 2026, 11:47 UTC

Earnings

AbbVie 1Q Global IMBRUVICA Rev $556M >ABBV

29 Apr 2026, 11:47 UTC

Earnings

AbbVie 1Q EPS 39c >ABBV

29 Apr 2026, 11:47 UTC

Earnings

AbbVie 1Q Net $695M >ABBV

29 Apr 2026, 11:47 UTC

Earnings

AbbVie 1Q International HUMIRA Rev $331M >ABBV

29 Apr 2026, 11:47 UTC

Earnings

AbbVie 1Q Rev $15B >ABBV

29 Apr 2026, 11:47 UTC

Earnings

AbbVie 1Q Adj EPS $2.65 >ABBV

29 Apr 2026, 11:47 UTC

Earnings

AbbVie 1Q U.S. HUMIRA Rev $357M >ABBV

29 Apr 2026, 11:47 UTC

Earnings

AbbVie Sees FY Adj EPS $14.08-Adj EPS $14.28 >ABBV

4 Feb 2026, 19:38 UTC

Earnings

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. -- Barrons.com

4 Feb 2026, 16:19 UTC

Earnings

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. -- Barrons.com

4 Feb 2026, 15:18 UTC

Earnings

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. -- Barrons.com

4 Feb 2026, 13:18 UTC

Earnings

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. -- Barrons.com

4 Feb 2026, 12:48 UTC

Earnings

AbbVie 4Q U.S. HUMIRA Rev $897M >ABBV

4 Feb 2026, 12:48 UTC

Earnings

AbbVie 4Q Rev $16.62B >ABBV

4 Feb 2026, 12:48 UTC

Earnings

AbbVie 4Q Global IMBRUVICA Rev $671M >ABBV

4 Feb 2026, 12:48 UTC

Earnings

AbbVie 4Q Global Skyrizi Rev $5.01B >ABBV

4 Feb 2026, 12:48 UTC

Earnings

AbbVie 4Q Net $1.82B >ABBV

4 Feb 2026, 12:48 UTC

Earnings

AbbVie 4Q Adj EPS $2.71 >ABBV

4 Feb 2026, 12:48 UTC

Earnings

AbbVie 4Q Global Net Rev From Oncology Portfolio $1.66B >ABBV

4 Feb 2026, 12:48 UTC

Earnings

AbbVie 4Q International HUMIRA Rev $349M >ABBV

4 Feb 2026, 12:48 UTC

Earnings

AbbVie Sees FY Adj EPS $14.37-Adj EPS $14.57 >ABBV

Peer Comparison

Price change

AbbVie Inc Forecast

Price Target

By TipRanks

25.99% upside

12 Months Forecast

Average 253.94 USD 25.99%

High 294 USD

Low 203 USD

Based on 20 Wall Street analysts offering 12 month price targets forAbbVie Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

20 ratings

Buy

Hold

Sell

Based on 20 analysts giving stock ratings to AbbVie Inc - Dist in the past 3 months.

Technical Score

By Trading Central

180.37 / 195.54Support & Resistance

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

There is one bearish event.

Sentiment

By Acuity

98 / 346 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.